A method of diagnosing bacterial vaginosis in a woman, which involves determining an amount of each of more than one BV-associated bacterium in a vaginal sample obtained from the female and assessing a BV status of the female based on the amount of each of the more than one BV-associated bacterium in the sample

Methods for the rapid detection of the presence or absence of mecA- and/or mecC-containing Staphylococcus aureus (mecA/mecC-MRSA) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the genes for mecA-MRSA and mecC-5 MRSA, along with kits are provided that are designed for the detection of mecA/mecC-MRSA.

The present application provides multiplex digital polymerase chain reaction (dPCR) assays such as multiplex drop-off dPCR assays, methods, systems, and kits. The methods described herein are useful in a variety of applications, such as detection of microsatellite instability and quantification of site-specific genome-edited products.

The present disclosure provides methods for predicting clinical response to therapy of a subject with an autoimmune disease or disorder and/or methods for predicting prognosis of a subject with immunodeficiency (e.g., leukemia) based on characterizing the B cell immune repertoire of the subject. In one aspect, methods provide for determining frequency of class switch recombination and/or somatic hypermutation of B cell receptor repertoires in samples prior to a treatment and predicting a subject's prognosis and/or response to treatment based on the measured class switching and/or somatic hypermutation frequency. In another aspect, methods provide for determination of immune receptor class switching and/or somatic hypermutation frequency and treating a subject based on the resulting prediction of prognosis and/or response to treatment based on the measured class switching and/or somatic hypermutation frequency.

A retrotransposable element-based multiplexed quantitative polymerase chain reaction (qPCR) assay system to quantitate and distinguish cell free DNA integrity and concentration in blood, plasma, and serum as a measure of minimum residual disease, therapeutic effectiveness, neoadjuvant effectiveness in a patient having stage I, stage II, stage III, or stage IV cancer, and disease progression, thereby improving patient outcomes.

Provided is a method for multiplex and asymmetric amplification of one or more target nucleic acids in a sample. The method can simultaneously amplify multiple target nucleic acids existing in a sample, and can simultaneously produce a large number of single-chain products.

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

The present disclosure provides methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a mixed sample of DNA comprising DNA from both the mother of the fetus and from the fetus, and optionally from genotypic data from the mother and father. The ploidy state is determined by using a joint distribution model to create a plurality of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern. The mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias, for example using massively multiplexed targeted PCR.

The purpose of the present invention is to provide a novel digital PCR analysis method. In the digital PCR analysis method disclosed herein, a method for detecting DNA is used, which includes the steps of: dividing a DNA solution containing a fluorescent-labeled probe or a DNA intercalator and a plurality of DNAs to be detected into a plurality of compartments; carrying out PCR in the compartments; measuring a fluorescence intensity in association with a change in temperature; calculating a melting temperature from a melting curve for a DNA double strand measured on the basis of a change in fluorescence intensity, which is associated with the change in temperature; and calculating a temperature difference between two points with a slope of a predetermined value on a melting curve indicating a change in the fluorescence intensity.

Disclosed is a gene panel which can evaluate lung adenocarcinoma molecular subtype and survival risk, and an application of a reagent, which detects the gene expression level of the gene panel, in preparing a product. The product is used for determining lung adenocarcinoma molecular subtype and evaluating lung adenocarcinoma patient survival risk. The product comprises a Next-Generation Sequencing (NGS) detection reagent kit, a fluorescence quantitative PCR detection reagent kit, a gene chip and a protein microarray. Also disclosed is a method which uses the detection reagent kits to evaluate lung adenocarcinoma molecular subtype and survival risk.